Most health plans and insurers would count qualifying payments for covered prescription drugs, including some manufacturer help, toward a person’s cost limits and deductible.
Most covered plans would count qualifying payments for prescription drugs, including permitted manufacturer help, toward a person’s cost limit and in-network deductible. Exceptions apply when certain lower-cost alternatives are available.
The Insurance Commissioner could fine health insurers that violate the counting rules, after notice and a chance to be heard.
Plans and insurers would count qualifying payments for covered drugs toward a person’s cost sharing, annual limit, and in-network deductible. This applies to most non-grandfathered health plans and insurance policies that provide essential health benefits. It excludes grandfathered coverage, certain specialized or supplemental coverage, and accident-only, specified-disease, and hospital-indemnity coverage. Payments made on a person’s behalf count only when the pharmacy tells the plan or insurer who received the help and how much was provided. The amount does not count when a lower-tier generic, an equally or less costly covered biosimilar, or a lower-cost nonprescription product with the same active ingredients is available and suitable; these exceptions do not apply when the person has legal coverage for a medically necessary nonpreferred or nonformulary drug. Manufacturer support remains subject to existing legal limits, and certain manufacturer payments are excluded. No start date is stated in the supplied text.
The Insurance Commissioner would be able to assess administrative penalties against insurers for violations. The penalties apply to health insurers that violate the bill’s requirements. The commissioner must provide appropriate notice and an opportunity for a hearing before ordering a penalty. The penalty may be up to $5,000 per violation, or up to $10,000 per violation if it was willful. No start date is stated in the supplied text.
No hearings or votes scheduled.